Evidence map›Paper›PMID 35145607›Full record

ArticleOncotarget2022

Antitumor effect of isoquercetin on tissue vasohibin expression and colon cancer vasculature.

Daniel de Castilho da Silva, Guilherme Di Camillo Orfali, Maycon Giovani Santana, Jessica Kaoru Yamamoto Palma, Isabella Ramos de Oliveira Assunção, Isadora Moraes Marchesi, Ana Yoshie Kitagawa Grizotto, Natália Peres Martinez, Simone Felliti, José Aires Pereira and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Therapeutic potential ofFrontiers in pharmacology · 2025
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Daniel de Castilho da SilvaProgramme Stricto Sensu in Health Science, Sao Francisco University Medical School, Sao Paulo, Brazil.
Guilherme Di Camillo OrfaliEscola Paulista de Medicina, São Paulo, Brazil.
Maycon Giovani SantanaScientific Initiation Programme, Sao Francisco University Medical School, Sao Paulo, Brazil.
Jessica Kaoru Yamamoto PalmaScientific Initiation Programme, Sao Francisco University Medical School, Sao Paulo, Brazil.
Isabella Ramos de Oliveira AssunçãoScientific Initiation Programme, Sao Francisco University Medical School, Sao Paulo, Brazil.
Isadora Moraes MarchesiEscola Paulista de Medicina, São Paulo, Brazil.
Ana Yoshie Kitagawa GrizottoEscola Paulista de Medicina, São Paulo, Brazil.
Natália Peres MartinezProgramme Stricto Sensu in Health Science, Sao Francisco University Medical School, Sao Paulo, Brazil.
Simone FellitiDepartment of Oncology, Sao Francisco University Medical School, Sao Paulo, Brazil.
José Aires PereiraDepartment of Pathology, Sao Francisco University Medical School, Sao Paulo, Brazil.
Denise Gonçalves PriolliPostgraduate Programme Stricto Sensu in Health Science, Sao Francisco University Medical School, Sao Paulo, Brazil.
Universidade São Francisco · BRAssociação Paulista de Medicina · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor cells trigger angiogenesis through the expression of angiogenic factors. Vasohibins (VASHs) are a family of peptides that regulate angiogenesis. Flavonoids have antiproliferative antitumor properties; however, few studies have highlighted their antiangiogenic potential. This study evaluated the flavonoid isoquercetin (Q3G) as an antitumor compound related to colon cancer vascularization and regulation of VASH1 and 2. Mice bearing xenogeneic colon cancer (

Indexed as

Colonic NeoplasmsNeovascularization, PathologicAngiogenic ProteinsAnimalsBevacizumabCell Cycle ProteinsMiceQuercetinXenograft Model Antitumor AssaysAngiogenic ProteinsBevacizumabCell Cycle ProteinsisoquercitrinQuercetinVASH2 protein, mouseangiogenic proteinsantitumor assays-xenograft modelflavonolsneoplasmstarget

Identifiers

PMID35145607
PMCPMC8823695
OpenAlexW4210885133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.